STOCK TITAN
  1. Home
  2. Sec-filings
  3. EW
  4. [Form 4] Edwards Lifesciences Corp Insider Trading Activity

Director at Edwards Lifesciences (NYSE: EW) receives 3,251 RSU grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

LAVIOLETTE PAUL A reported acquisition or exercise transactions in this Form 4 filing.

Edwards Lifesciences Corp director Paul A. LaViolette received an equity grant of 3,251 restricted stock units on May 8, 2026. The award was granted at no cash price under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. These restricted stock units are scheduled to become 100% vested after the earlier of one year from the grant date or the company’s next annual meeting of stockholders. Following this grant, LaViolette directly holds 17,552 shares of common stock.

Positive

  • None.

Negative

  • None.
Insider LAVIOLETTE PAUL A
Role null
Type Security Shares Price Value
Grant/Award Common Stock 3,251 $0.00 --
Holdings After Transaction: Common Stock — 17,552 shares (Direct, null)
Footnotes (1)
  1. [object Object]
RSUs granted 3,251 restricted stock units Granted to director Paul A. LaViolette on May 8, 2026
Grant price $0.00 per share Equity award under 2020 Nonemployee Directors Stock Incentive Program
Shares after transaction 17,552 shares Total common stock directly held following the grant
restricted stock units financial
"These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2020 Nonemployee Directors Stock Incentive Program financial
"granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program."
vested financial
"They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders."
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LAVIOLETTE PAUL A
(Last)(First)(Middle)
ONE EDWARDS WAY
(Street)
IRVINE CALIFORNIA 92614
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/08/2026A3,251(1)A$0.000017,552D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.
Remarks:
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.
/s/ Paul A. LaViolette05/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Edwards Lifesciences (EW) report for Paul A. LaViolette?

Edwards Lifesciences reported that director Paul A. LaViolette received 3,251 restricted stock units on May 8, 2026. The award was granted at no cash price as part of the company’s 2020 Nonemployee Directors Stock Incentive Program.

How many shares does Paul A. LaViolette hold after this Edwards Lifesciences Form 4 filing?

After the reported transaction, Paul A. LaViolette directly holds 17,552 shares of Edwards Lifesciences common stock. This total reflects his position following the grant of 3,251 restricted stock units disclosed in the Form 4 filing.

Was the Edwards Lifesciences (EW) Form 4 transaction an open-market stock purchase?

No, the transaction was not an open-market purchase. Director Paul A. LaViolette received 3,251 restricted stock units as a grant at a price of $0.00 per share under the company’s 2020 Nonemployee Directors Stock Incentive Program.

What is the vesting schedule for Paul A. LaViolette’s 3,251 restricted stock units at Edwards Lifesciences?

The 3,251 restricted stock units are scheduled to become 100% vested after the earlier of one year from the May 8, 2026 grant date or Edwards Lifesciences’ next annual meeting of stockholders, according to the Form 4 footnote.

Under which plan were the new restricted stock units for Edwards Lifesciences director granted?

The restricted stock units were granted under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. This plan governs equity awards made to nonemployee directors, including the 3,251-unit grant to Paul A. LaViolette.